This is particularly important in pancreatic cancer chemotherapy because more than 50% of pancreatic cancers have inactivated Smad4 protein [20], which may result in activation of the Smad4-independent TGF-β1 pathway when patients undergo such treatment. The gene discussed is TGFB1; the disease is pancreatic neoplasm.